Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Regains Compliance with Nasdaq Listing Requirement, Works to Meet Another Requirement

NEW YORK (GenomeWeb) – Genetic Technologies said today that it regained compliance with a listing requirement for continued listing on the Nasdaq, while the exchange has extended a deadline for the company to regain compliance with another requirement. 

In August Nasdaq sent a letter to Genetic Technologies informing the firm that it wasn't in compliance with a Nasdaq listing rule calling for a minimum $1 bid on the company's shares, and as a result the firm faced a possible delisting action. 

Last month Melbourne, Australia-based Genetic Technologies undertook a reverse stock split, in which the ratio of one American depositary receipt (ADR) representing 30 shares of the company's stock was increased to a ratio of one ADR representing 150 shares. As a result of that reverse stock split, Nasdaq told the company today that it has regained compliance and the matter has been closed. 

Also, Genetic Technologies said that Nasdaq has extended the deadline for it to regain compliance with a listing requirement of a minimum of $2.5 million in shareholders' equity. In November Genetic Technologies was told by Nasdaq that for its fiscal year 2014 ended June 30, it had shareholders' equity of about $1.7 million. Nasdaq gave the firm until Dec. 22, 2014 to submit a plan to regain compliance. 

Genetic Technologies submitted its plan in November and was told in late January by Nasdaq that it has extended the deadline to May 4 for Genetic Technologies to regain compliance with the listing rule. 

In afternoon trading today, Genetic Technologies' shares were up 28 percent at $3.97.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.